Business
Electromedical Technologies Clarifies Comparative Six-Month Highlights Reported in August 18, 2021 Press Release
Electromedical Technologies Clarifies Comparative Six-Month Highlights Reported in August 18, 2021 Press Release.
About this update from Electromedical Technologies, Inc.
[{"type":"text","content":"\n\n\n\nElectromedical Technologies Clarifies Comparative Six-Month Highlights Reported in August 18, 2021 Press Release\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nElectromedical Technologies Clarifies Comparative Six-Month Highlights Reported in August 18, 2021 Press Release\nPR Newswire\nSCOTTSDALE, Ariz., Aug. 19, 2021\n\n\n\nSCOTTSDALE, Ariz., Aug. 19, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the \"Company\"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, clarifies and corrects its previously published press release disclosing comparative results from the six months ended June 30, 2021 versus June 30, 2020.\nSix Months ended June 30, 2021 Highlights\nRevenue increased to $369,394 up from $351,625, a roughly 5% increase over the six months ended June 30, 2020. Selling, General, and Administrative expenses increased by approximately $842,435, to $2,367,254, up 55% from the $1,524,819 recorded during the six months ended June 30, 2020. Net loss from operations was ($2,089,192) versus ($1,255,702) during the six months ended June 30, 2020. Total net loss increased to ($3,334,916), or ($0.10) per share, from ($1,291,496), or ($0.07), for the six months ended June 30, 2020. About Electromedical Technologies\nHeadquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traum...